热景生物上半年亏损 2019上市募4.6亿扣非连亏2年半

Core Viewpoint - The company reported a significant decline in revenue and increased net losses for the first half of 2025 compared to the same period in the previous year [1][2]. Financial Performance - For the first half of 2025, the company achieved operating revenue of 204 million yuan, a year-on-year decrease of 18.04% [1][2]. - The net profit attributable to shareholders was -83.99 million yuan, compared to -43.47 million yuan in the same period last year [2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -90.05 million yuan, worsening from -76.83 million yuan year-on-year [2]. - The net cash flow from operating activities was 17.37 million yuan, a significant improvement from -3.84 million yuan in the previous year [2]. Historical Context - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on September 30, 2019, with an initial issuance of 15.55 million shares at a price of 29.46 yuan per share [3]. - In 2024, the company reported total operating revenue of 51.09 million yuan, a decrease of 7.62% year-on-year, and a net loss of -17.92 million yuan compared to a profit of 2.85 million yuan in 2023 [3]. Shareholder Activity - The company disclosed that a major shareholder, Tongcheng Rejing, completed a share reduction plan, selling 1.8 million shares between April 15 and June 5, 2025, raising 214 million yuan [4]. - The actual controller of the company, Lin Changqing, plans to reduce his holdings by up to 1 million shares due to personal funding needs [4].